LifeStance Health Group (NASDAQ:LFST) Earns Buy Rating from Analysts at BTIG Research

Key Points

• BTIG Research has initiated coverage on LifeStance Health Group (NASDAQ:LFST) with a "buy" rating and a price target of $8.00, indicating a potential upside of 93.14% from its current stock price.
• Multiple research firms, including Canaccord Genuity and UBS Group, have similarly issued "buy" ratings for LifeStance Health Group, reflecting a consensus rating of "Moderate Buy" with a target price averaging $8.42.
• The stock is currently traded at $4.14 with a market cap of $1.61 billion, and it has shown a high of $8.61 and a low of $4.09 in the past twelve months.
• Insider trading activity includes a significant sell by an insider, who sold 16,000 shares at an average price of $5.94, reducing their stake by 12.36%.

Investment analysts at BTIG Research began coverage on shares of LifeStance Health Group (NASDAQ:LFST - Get Free Report) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $8.00 price target on the stock. BTIG Research's target price would suggest a potential upside of 93.14% from the company's current price.

A number of other research firms have also recently weighed in on LFST. Canaccord Genuity Group started coverage on LifeStance Health Group in a research report on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price objective for the company. UBS Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 target price on the stock in a report on Tuesday, May 27th. Finally, KeyCorp began coverage on shares of LifeStance Health Group in a research note on Tuesday, April 8th. They set an "overweight" rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.42.

LifeStance Health Group Stock Up 0.0%

LifeStance Health Group stock traded up $0.00 during mid-day trading on Friday, reaching $4.14. 106,036 shares of the company were exchanged, compared to its average volume of 1,835,370. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.47. The firm has a market cap of $1.61 billion, a P/E ratio of -41.45 and a beta of 1.16. The business has a fifty day moving average of $5.16 and a 200 day moving average of $6.48. LifeStance Health Group has a 12-month low of $4.09 and a 12-month high of $8.61.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ujjwal Ramtekkar sold 16,000 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $5.94, for a total transaction of $95,040.00. Following the transaction, the insider owned 113,435 shares in the company, valued at approximately $673,803.90. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of large investors have recently made changes to their positions in LFST. Parcion Private Wealth LLC purchased a new position in LifeStance Health Group in the 1st quarter valued at about $15,670,000. Dimensional Fund Advisors LP lifted its holdings in LifeStance Health Group by 87.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock valued at $25,977,000 after purchasing an additional 1,643,390 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in LifeStance Health Group in the 1st quarter valued at about $7,932,000. Nuveen LLC acquired a new position in shares of LifeStance Health Group during the 1st quarter valued at about $6,928,000. Finally, Vanguard Group Inc. increased its stake in shares of LifeStance Health Group by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 10,689,396 shares of the company's stock valued at $78,781,000 after acquiring an additional 784,818 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.